 AIM ImmunoTech Inc posted second-quarter results that demonstrated that it is in a strong financial position with 57.3 million to press ahead with clinical trials and execute on its corporate strategy. For the period ended June 30, 2021, the Ocala, Florida-based immuno-pharma company had cash, equivalents and marketable securities of 57.3 million, compared to 54.4 million as of December 31, 2020. 